NCT01365104

Modulation of Cerebral Blood Flow Using Iron Chelators

Hypoxia-Inducible Transcription Factor 1 (HIF-1)in Vascular Aging

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 97 (actual)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

Conditions

• Stroke
• Problem of Aging

Interventions

Type	Name	Description
DRUG	desferrioxamine	intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.

Timeline

• Start date: 2008-03-01
• Primary completion: 2012-06-01
• Completion: 2014-12-01
• First posted: 2011-06-03
• Last updated: 2015-01-28

Locations

1 site across 1 country: United States